BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Similarly, greater Cmin of nilotinib, a selective break point cluster-Abelson (BCR-ABL) TKI, was associated with shorter time to complete cytogenetic response, shorter time to major molecular response, longer time to progression, and a trend toward higher response rates in patients with chronic myeloid leukemia [35].